Daniele Calistri
University of Pavia
146 Papers
932 Citations
Daniele Calistri is an academic researcher from University of Pavia. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 32, co-authored 132 publications.
Chat about Author
Papers
PI-PLCβ1 gene copy number alterations in breast cancer.
Chiara Molinari,Laura Medri,Matilde Y. Follo,Manuela Piazzi,Giulia Adalgisa Mariani,Daniele Calistri,Lucio Cocco +6 more
TL;DR: The findings indicate that the amplification of the PI-PLCβ1 gene amplification was mostly related to the mitotic index, rather than to the invasion status, and the case series is limited, so it seems to be correlated to clinicopathological parameters.
Discrepancies between VEGF −1154 G>A Polymorphism Analysis Performed in Peripheral Blood Samples and FFPE Tissue
TL;DR: The findings indicate that, although FFPE tissue might be a suitable specimen for genotyping, VEGF −1154 does not give reliable results on this type of material, and as other SNPs may also have this limitation, genotype concordance should first be confirmed by comparing results obtained from FFPe and fresh sample analyses.
11
Clinical and Genetic Factors Related to Cancer-Induced Bone Pain and Bone Pain Relief
Emanuela Scarpi,Daniele Calistri,Pål Klepstad,Stein Kaasa,Frank Skorpen,Ragnhild Habberstad,Oriana Nanni,Dino Amadori,Marco Maltoni +8 more
TL;DR: Patients with CIBP who were taking opioids had a clinical profile slightly different from that of the non-CIBP group, however, no specific genetic pattern emerged for C IBP versus non-cIBP or for responsive versus nonresponsive patients with CibP.
10
LOH 19q indicates shorter disease progression-free interval in low-grade oligodendrogliomas with EMP3 methylation.
Alice Pasini,P. Iorio,Emanuela Bianchi,Serenella Cerasoli,Anna Maria Cremonini,Marina Faedi,Carlo Guarnieri,Graziano Guiducci,Luca Riccioni,Chiara Molinari,Claudia Rengucci,Daniele Calistri,Emanuele Giordano +12 more
TL;DR: A total (cytogenetic and epigenetic) functional loss of both EMP3 alleles accounts for the reduced disease progression-free interval in OII patients and support testing this hypothesis in larger cohorts of patients.
Predictive molecular markers for EGFR-TKI in non-small cell lung cancer patients: new insights and critical aspects
TL;DR: An overview of the most important molecular predictive markers for EGFR-TKIs therapy in NSCLC patients is provided, and attention is focused on biological samples suitable for analysis and alternative sampling approaches such as plasma- or serum-derived DNA.
10